Leukemia Research Foundation News

Leukemia Research Foundation Earns Top Distinction from Charity Navigator

 

Northfield, Illinois (July 8, 2021) – The Leukemia Research Foundation has earned the highest possible rating of four stars from Charity Navigator, America’s largest independent charity evaluator. This is the fourth time the Leukemia Research Foundation has earned this top distinction in the last seven years.

Charity Navigator only awards four stars to the most exceptional organizations, evaluating them based on metrics of financial health, accountability, and transparency. The purpose of the rating is to show donors how efficiently a charity will use their support, how well it has sustained its programs and services over time, and its level of commitment to accountability and transparency.

“The Leukemia Research Foundation’s exceptional 4-star rating sets it apart from its peers and demonstrates its trustworthiness to the public,” according to Michael Thatcher, president and CEO of Charity Navigator. “Only a quarter of charities rated by Charity Navigator receive the distinction of our 4-star rating.”

The Leukemia Research Foundation joins other well-known organizations at the top of Charity Navigator’s list, including the Alzheimer’s Foundation of America, Ronald McDonald House Charities, and United Way Worldwide.

“We are dedicated to conquering leukemia by funding research into their causes and cures, and enriching the quality of life of those touched by these diseases,” said Kevin Radelet, executive director of the Leukemia Research Foundation. “In doing so, we are strongly committed to the most principled and transparent practices. This prestigious rating from Charity Navigator reflects what our donors expect from us every day.”

Detailed information about the Leukemia Research Foundation’s rating can be found on Charity Navigator’s website.

Charity Navigator Four Star Rating

Subscribe

Honoring Pop: My Personal Fight Against Leukemia

FDA Approves Iclusig Plus Chemo for Ph+ ALL

Blina may be effective in first-line treatment of Pediatric B-ALL